Vertex Pharmaceuticals Shares Acquired by Mirae Asset Global Investments

Pharmaceutical company's stock sees increased institutional investment

Apr. 17, 2026 at 11:20am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate pharmaceutical manufacturing equipment, including gears, pipes, and other industrial components, conveying the technological sophistication and scale of Vertex's drug development process.Institutional investors see Vertex Pharmaceuticals' specialized drug manufacturing capabilities as a key asset.Boston Today

Mirae Asset Global Investments Co. Ltd. has increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.4% during the fourth quarter, according to a recent SEC filing. The investment firm now owns 174,347 shares of the pharmaceutical company's stock, valued at $79,042,000.

Why it matters

Vertex Pharmaceuticals is a leading biotechnology company focused on developing treatments for serious diseases like cystic fibrosis. The increase in institutional investment signals confidence in the company's pipeline and future growth prospects.

The details

According to the 13F filing, Mirae Asset Global Investments acquired an additional 23,291 shares of Vertex Pharmaceuticals during the fourth quarter. This brings the firm's total stake in the company to 0.07% of outstanding shares. Other institutional investors have also been increasing their positions in Vertex, with firms like Brighton Jones LLC, Gamco Investors, and NewEdge Advisors all boosting their holdings in recent quarters.

  • Mirae Asset Global Investments reported the increased stake in Vertex Pharmaceuticals in its Q4 2025 13F filing.
  • The filing covers the period from October 1, 2025 to December 31, 2025.

The players

Mirae Asset Global Investments Co. Ltd.

A global asset management firm that has increased its stake in Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing treatments for serious diseases like cystic fibrosis.

Got photos? Submit your photos here. ›

What they’re saying

“Vertex Pharmaceuticals' pipeline and growth prospects continue to attract strong institutional interest.”

— Analyst

The takeaway

The increased investment in Vertex Pharmaceuticals by Mirae Asset Global Investments and other institutional investors underscores the company's position as a leader in the biotechnology industry and the confidence in its ability to deliver innovative treatments for serious diseases.